Roche's Chugai claims Alexion co-opted its patented tech in building Ultomiris

Alexion has a lot riding on the launch for Ultomiris, its long-acting follow-up to Soliris. But Roche's Chugai says Ultomiris' 8-week dosing schedule depends on its own patented drug-delivery technology—and it's asking a judge to stop the new launch in its tracks.